Mike Zaman's  Instablog

Mike Zaman
Send Message
  • MannKind (MNKD) Mega Million Deal For Inhaled Insulin Therapy, Magic Software Enterprises (MGIC) Double-Digit Growth Momentum 0 comments
    Aug 11, 2014 7:36 AM | about stocks: MNKD, MGIC, SNY

    https://staticseekingalpha.a.ssl.fastly.net/uploads/2014/8/11/saupload_mnkd.jpg MannKind Corp. (NASDAQ:MNKD)

    Glucose comes from carbohydrate foods. It is the main source of energy used by the body. Insulin is a hormone that helps your body's cells use the glucose. Insulin is produced in the pancreas and released into the blood when the amount of glucose in the blood rises.

    Diabetes, often referred to by doctors as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body's cells do not respond properly to insulin, or both.

    Patients with high blood sugar will typically experience polyuria (frequent urination), they will become increasingly thirsty (polydipsia) and hungry (polyphagia).

    The first main type of diabetes is type 1 diabetes, an autoimmune disease where the pancreas produces very little insulin or no insulin at all.

    Type 2 diabetes is normally found in people who are overweight as they get older. Although it is sometimes called adult onset diabetes, in some countries, such as the U.S., more children and young adults are being diagnosed with type 2 diabetes because they are not getting enough activity.

    About 90% of all cases of diabetes are type 2 diabetes. The difference between type 1 and type 2 diabetes is that with type 2 diabetes the pancreas does not produce enough insulin or the body does not properly use the it.

    Blood glucose levels that remain high over time can damage your eyes, kidneys, nerves, and blood vessels.

    MNKD and Sanofi reported that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza(NYSE:R) (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.

    Under the terms of the agreement, MNKD will receive an upfront payment of $150 million and potential milestone payments of up to $775 million. The milestone payments are dependent upon specific regulatory and development targets, as well as sales thresholds.

    Sanofi and MNKD will share profits and losses on a global basis, with Sanofi retaining 65% and MNKD receiving 35%. Sanofi has agreed to advance to MNKD its share of the collaboration's expenses up to a limit of $175 million.

    Sanofi will be responsible for global commercial, regulatory and development activities, while MNKD will manufacture Afrezza

    Afrezza is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adult patients with diabetes mellitus. The product consists of Afrezza Inhalation Powder delivered using an inhaler. Administered at the start of a meal, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of administration, and decline to baseline by approximately 180 minutes


    MNKD focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.

    More about MannKind Corp. (MNKD) at www.mannkindcorp.com


    https://staticseekingalpha.a.ssl.fastly.net/uploads/2014/8/11/saupload_mgic.jpg Magic Software Enterprises Ltd. (NASDAQ:MGIC)

    On its financial results, MGIC reported strong performance in sales and profitability across the company's products and professional services.

    For the second quarter 2014, MGIC posted revenues of $40.6 million, a 17% increase year over year, operating income of $5.1 million, a 26% increase compared to the same period the prior year, and net income of $3.9 million (or $0.09 per fully diluted share) compared to $3.5 million in the second quarter 2013, while its Non-GAAP net income increased 24% to $4.7 million versus the comparable period last year.


    MGIC is a global provider of mobile and cloud-enabled application and business integration platforms.

    More about Magic Software Enterprises Ltd. (MGIC) at www.magicsoftware.com.


    Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: MNKD, MGIC, SNY
Back To Mike Zaman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.